ALKERMES reported $1.57B in Debt for its fiscal quarter ending in September of 2026.





Debt Change Date
AbbVie USD 70.82B 2.04B Jun/2026
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
ALKERMES USD 1.57B 10.58M Sep/2026
Amgen USD 57.3B 19M Jun/2026
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 54.91B 11.54B Jun/2026
Gilead Sciences USD 26.25B 4.07B Jun/2026
Heron Therapeutics USD 149.65M 157K Sep/2024
Ionis Pharmaceuticals USD 1.77B 141M Sep/2026
J&J USD 49.04B 5.95B Jun/2026
Malin Corporation EUR 100K 0 Dec/2023
Merck USD 53.91B 4.79B Jun/2026
Minerva Neurosciences USD 0 0 Sep/2024
Nektar Therapeutics USD 0 0 Jun/2022
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Otsuka Holdings JPY 191.49B 2.71B Sep/2026
Ovoca Bio EUR 0 0 Jun/2021
Pfizer USD 62.67B 523M Sep/2026
Regeneron Pharmaceuticals USD 2.71B 400K Jun/2026
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026